Is It Too Soon To Start Reporting HER2 Genetic Heterogeneity?-Reference-Cited by-同舟云学术

Is It Too Soon To Start Reporting HER2 Genetic Heterogeneity?

Published:2010-02-01 Issue:2 Volume:134 Page:162-163
ISSN:1543-2165
Container-title:Archives of Pathology & Laboratory Medicine
language:en
Short-container-title:

Author:

Albarracin Constance¹,Edgerton Mary E.¹,Gilcrease Michael Z.¹,Huo Lei¹,Krishnamurthy Savitri¹,Middleton Lavinia P.¹,Resetkova Erika¹,Sahin Aysegul A.¹,Sneige Nour¹,Fraser W. Symmans¹,Wu Yun¹

Affiliation:

1. Department of Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030

Publisher

Archives of Pathology and Laboratory Medicine

Subject

Medical Laboratory Technology,General Medicine,Pathology and Forensic Medicine

Link

http://meridian.allenpress.com/aplm/article-pdf/134/2/162/2769007/1543-2165-134_2_162_b.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity;Modern Pathology;2021-05-12

2. Accurate Assessment of Human Epidermal Growth Factor Receptor 2;Journal of Clinical Oncology;2012-05-10

3. ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases;Modern Pathology;2012-01-27

4. Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations;American Journal of Clinical Pathology;2011-12-01

5. Relationship between pathological features, HER2 protein expression andHER2and CEP17 copy number in breast cancer: biological and methodological considerations;Journal of Clinical Pathology;2010-12-22